Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAF-189s vs platinum-based chemotherapy as adjuvant therapy in resected stage II–IIIB ALK/ROS1-positive NSCLC
ChiCTR2500109405Phase 3Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of foritinib in ALK-positive non-small cell lung cancer and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: Disease-free survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
foritinib
03
Conditions
ALK-positive non-small cell lung cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500109405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109405.